Associate Professor of Hematology and Oncology, Emory University
Oncology
Dr. Ruth M. O'Regan, MD
|
|
Give Review
Ruth O'Regan works in the field of Oncology. She researched medicine at Medical College of Wisconsin Affiliated Hospitals. She has 3 awards "America's Top Doctors", "Atlanta Magazine: Top Doctors" and "America's Top Doctors for Cancer". Doctor Ruth M. O'Regan, MD is a published doctor as well. She has 69 publications published. The latest was: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Publications
- Systemic therapy for early-stage HER2-positive breast Cancers: time for a less-is-more approach?
- Molecular Homology and Difference between Spontaneous Canine Mammary Cancer and Human Breast Cancer.
- Breast Cancer screening: Time for rational discourse.
- Everolimus: side effect profile and management of toxicities in breast Cancer.
- Genomic subtypes in choosing adjuvant therapy for breast Cancer.
- New and emerging treatments for estrogen receptor-positive breast Cancer: focus on everolimus.
- The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
- Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008.
- Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in Breast carcinoma.
- Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance.
- 21-Gene recurrence scores: Racial differences in testing, scores, treatment, and outcome.
- Combinatorial effects of Lapatinib and rapamycin in triple-negative breast Cancer cells.
- The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy.
- Identifying subsets of metastatic breast Cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone.
- Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway.
- Age/race differences in HER2 testing and in incidence rates for breast Cancer triple subtypes: a population-based study and first report.
- Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast Cancer cells via transactivation of epiderm...
- Proton-sponge coated quantum dots for siRNA deLivery and intracellular imaging.
- Targeted glycoproteomic identification of biomarkers for human Breast carcinoma.
- Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate Cancer cells.
- A phase II study of single agent bortezomib in patients with metastatic breast Cancer: a single institution experience.
- Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast Cancer cells.
- Development and therapeutic options for the treatment of raloxifene-stimulated breast Cancer in athymic mice.
- Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast Cancer.
- Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast Cancer.
- Do tumors detected by mammography screening have a favorable prognosis?
- New targeted therapies in breast Cancer.
- Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial Cancer growth in vivo.
- Effects of raloxifene after tamoxifen on Breast and endometrial tumor growth in athymic mice.
- A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
- Biomedical nanotechnology for molecular imaging, profiling, and drug targeting.
- Review: bisphosphonates prevent or delay skeletal events in women with advanced breast Cancer and bone metastases.
- Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation.
- mTOR inhibition in breast Cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
- Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast Cancer pretreated with trastuzumab.
- Adjuvant anthracyclines: time for a change of heart?
- Tamoxifen and contralateral breast Cancer.
- Using National Quality Forum breast Cancer indicators to measure quality of care for patients in an AVON comprehensive breast center.
- Inorganic nanoparticles for predictive oncology of breast Cancer.
- Treatment adherence and outcome in women with inflammatory breast Cancer: does race matter?
- Selection of optimal adjuvant endocrine therapy for early-stage breast Cancer.
- Antiestrogen stimulated human endometrial Cancer growth: laboratory and clinical considerations.
- Endocrine therapy for the treatment of postmenopausal women with breast Cancer.
- Improving on national quality indicators of breast Cancer care in a large public hospital as a means to decrease disparities for African American women.
- Characteristics and treatment modalities for African American women diagnosed with stage III breast Cancer.
- Reciprocal regulation of ZEB1 and AR in triple negative breast Cancer cells.
- Adjuvant chemotherapy: how much is enough?
- Increased HER2/neu expression in recurrent hormone receptor-positive breast Cancer.
- Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.
- In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast Cancer cells.
- Emerging use of nanoparticles in diagnosis and treatment of breast Cancer.
- Race and triple negative threats to breast Cancer survival: a population-based study in Atlanta, GA.
- Targeting angiogenesis in advanced breast Cancer.
- Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.
- Progress in systemic adjuvant therapy of early-stage breast Cancer.
- The evolution of tamoxifen therapy in breast Cancer: selective oestrogen-receptor modulators and downregulators.
- New strategies for the treatment of breast Cancer.
- Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial Cancer growth in athymic mice.
- Selective estrogen-receptor modulators in 2001.
- Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast Cancer xenografts.
- Tamoxifen to raloxifene and beyond.
- Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated Breast tumors grown in athymic mice.
- Rapid development of tamoxifen-stimulated mutant p53 Breast tumors (T47D) in athymic mice.
- Antitumor action of physiological estradiol on tamoxifen-stimulated Breast tumors grown in athymic mice.
- Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial Cancer growth.
- Farnesyl transferase inhibitors: the next targeted therapies for breast Cancer?
- Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiolo...
- Laboratory models of breast and endometrial Cancer to develop strategies for antiestrogen therapy.
Schools
University College Dublin National University Of Ireland School Of Medicine and Medical Science
Mater Hospital
Med College Of Wisconsin
Northwestern University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Atlanta Magazine: Top Doctors
- America's Top Doctors for Cancer
Education
-
McGaw Medical Center of Northwestern University -
Medical College of Wisconsin Affiliated Hospitals -
University College of Dublin National Univ SOM
Drug Facts
| NPI NUMBER | 1215981238 | |
| NPPES Provider LastName | O'REGAN | |
| NPPES Provider FirstName | RUTH | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 831.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 2.29 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215981238 |
| Last Name Of The Provider | O'REGAN |
| First Name Of The Provider | RUTH |
| View All |
Similar Doctors
|
|
Dr. Rein Saral, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nabil F. Saba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Torey B. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vasileios J. Assikis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret K. Offermann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amelia B. Zelnak, MD
This Doctor is OpenDoctor Recommended.
|